RxDoctor Payments Data

Daniel Kloster, MD

Interventional Pain Medicine · Overland Park, KSNPI 1346237088

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (57.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Spinal Simplicity, LLC at 34.3% of the total. Reporting peaked in 2020 at $195,932 and has fallen 64.3% since, to $70,037 in 2025.

$876,351in general payments, 2019–2025

Across 916 payments — averaging $956.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Spinal Simplicity, LLC$300K
  • Flowonix Medical Incorporated$156K
  • Boston Scientific$94K
  • Omnia Medical, LLC$82K
  • Vertiflex, Inc.$73K
  • Neuroone Medical Technologies Corporation$65K
  • plus $105K from 24 others
$571,886in research payments, 2019–2025

Across 177 payments — averaging $3230.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$343K
  • Flowonix Medical Incorporated$115K
  • Nevro Corp.$61K
  • Vertos Medical, Inc.$25K
  • Si-bone, Inc.$22K
  • Spinal Simplicity, LLC$6K
  • plus $500 from 1 others
$70,496in ownership & investment interests, 2019–2025

Across 6 payments — averaging $11,749 each. An ownership or investment interest held by the physician or an immediate family member.

  • Spinal Simplicity, LLC$70K

What the payments were for

  • Consulting fees$501,63257%
  • Speaking & faculty fees$159,88618%
  • Travel & lodging$90,75110%
  • Food & beverage$41,5265%
  • Education$82,5279%
  • Entertainment$290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional pain medicine providers in Kansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$336,775
Medicare patients
490
Services billed
3,592

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen109$2,460
Morphine Sulfate ErMorphine Sulfate52$1,727
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen61$1,673
Methadone Hcl59$1,255
Gabapentin60$879
Cyclobenzaprine Hcl51$840
Nortriptyline Hcl33$629
Oxycodone Hcl56$620
Tramadol Hcl66$478
Tizanidine Hcl16$282
Methylprednisolone11$57

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →